Hixozide in therapy of tuberculosis of bronchi

The purpose of the article is to evaluate the efficacy and tolerability of the combined inhaled anti-TB preparation Hixozide for improving the effectiveness of medical treatment of patients suffering from tuberculosis of bronchus. Material and Methods. Hixozide (made in Russia), the active substance...

Full description

Bibliographic Details
Main Authors: Morozova T.l., Barinboym O.N., Doktorova N.P., Danilov A.N.
Format: Article
Language:Russian
Published: Saratov State Medical University 2014-06-01
Series:Саратовский научно-медицинский журнал
Subjects:
Online Access:http://www.ssmj.ru/system/files/2014_02_293-300.pdf
_version_ 1818665403810840576
author Morozova T.l.
Barinboym O.N.
Doktorova N.P.
Danilov A.N.
author_facet Morozova T.l.
Barinboym O.N.
Doktorova N.P.
Danilov A.N.
author_sort Morozova T.l.
collection DOAJ
description The purpose of the article is to evaluate the efficacy and tolerability of the combined inhaled anti-TB preparation Hixozide for improving the effectiveness of medical treatment of patients suffering from tuberculosis of bronchus. Material and Methods. Hixozide (made in Russia), the active substance Hydroxymethylchinoxylindioxydum 100mg + Isoniazidum 250 mg, was delivered via inhalations using a compressor nebulizer within 21 days in the course of the complex chemotherapy. Inclusion criteria: newly diagnosed patients and patients with relapsed tuberculosis with the presence of tuberculousendobronchitis, drug sensitivity saved to isoniazid. Exclusion criteria: the state of preventing the appointment of adequate treatment, HIV-infection (group 1, n=30). The comparison group was consisted of patients receiving standard treatment in combination with inhaled administration of Isoniazid (group 2, n=21). Rezults. The clinical study has figured out: after a course of inhalations of Hixozide the clinical cure of bronchial tuberculosis occurs after the period of 2 months of treatment (according to the results of endoscopy of bronchi); more patients — 69.2% versus 38.1% in the comparison group, p=0,039 showed a positive trend during the nonspecific endobronchitis — 85,7% vs. 52,9%, p=0,017; the treatment and bacteriological conversion were achieved: 143±27 days in the first group vs. 164±32 days in the control group, p=0,019. Adverse reactions to Hixozide demanding its abolition occurred in 13,3%, they were stopped and did not affect the health of patients in the future. Conclusion. Inhaled Hixozide in the complex treatment of patients with tuberculosis accelerates clinical cure of tuberculosis of the bronchi, healing the lesions in the lung tissue and abacillation.
first_indexed 2024-12-17T05:48:05Z
format Article
id doaj.art-3bdbd7578f2240929e7690330d1cf9e1
institution Directory Open Access Journal
issn 2076-2518
language Russian
last_indexed 2024-12-17T05:48:05Z
publishDate 2014-06-01
publisher Saratov State Medical University
record_format Article
series Саратовский научно-медицинский журнал
spelling doaj.art-3bdbd7578f2240929e7690330d1cf9e12022-12-21T22:01:15ZrusSaratov State Medical UniversityСаратовский научно-медицинский журнал2076-25182014-06-011022933003690Hixozide in therapy of tuberculosis of bronchiMorozova T.l.0Barinboym O.N.1Doktorova N.P.2Danilov A.N.3Saratov State Medical UniversitySaratov State Medical UniversitySaratov State Medical UniversitySaratov State Medical UniversityThe purpose of the article is to evaluate the efficacy and tolerability of the combined inhaled anti-TB preparation Hixozide for improving the effectiveness of medical treatment of patients suffering from tuberculosis of bronchus. Material and Methods. Hixozide (made in Russia), the active substance Hydroxymethylchinoxylindioxydum 100mg + Isoniazidum 250 mg, was delivered via inhalations using a compressor nebulizer within 21 days in the course of the complex chemotherapy. Inclusion criteria: newly diagnosed patients and patients with relapsed tuberculosis with the presence of tuberculousendobronchitis, drug sensitivity saved to isoniazid. Exclusion criteria: the state of preventing the appointment of adequate treatment, HIV-infection (group 1, n=30). The comparison group was consisted of patients receiving standard treatment in combination with inhaled administration of Isoniazid (group 2, n=21). Rezults. The clinical study has figured out: after a course of inhalations of Hixozide the clinical cure of bronchial tuberculosis occurs after the period of 2 months of treatment (according to the results of endoscopy of bronchi); more patients — 69.2% versus 38.1% in the comparison group, p=0,039 showed a positive trend during the nonspecific endobronchitis — 85,7% vs. 52,9%, p=0,017; the treatment and bacteriological conversion were achieved: 143±27 days in the first group vs. 164±32 days in the control group, p=0,019. Adverse reactions to Hixozide demanding its abolition occurred in 13,3%, they were stopped and did not affect the health of patients in the future. Conclusion. Inhaled Hixozide in the complex treatment of patients with tuberculosis accelerates clinical cure of tuberculosis of the bronchi, healing the lesions in the lung tissue and abacillation.http://www.ssmj.ru/system/files/2014_02_293-300.pdfHixozidetreatment of tuberculosistuberculosis of bronchi
spellingShingle Morozova T.l.
Barinboym O.N.
Doktorova N.P.
Danilov A.N.
Hixozide in therapy of tuberculosis of bronchi
Саратовский научно-медицинский журнал
Hixozide
treatment of tuberculosis
tuberculosis of bronchi
title Hixozide in therapy of tuberculosis of bronchi
title_full Hixozide in therapy of tuberculosis of bronchi
title_fullStr Hixozide in therapy of tuberculosis of bronchi
title_full_unstemmed Hixozide in therapy of tuberculosis of bronchi
title_short Hixozide in therapy of tuberculosis of bronchi
title_sort hixozide in therapy of tuberculosis of bronchi
topic Hixozide
treatment of tuberculosis
tuberculosis of bronchi
url http://www.ssmj.ru/system/files/2014_02_293-300.pdf
work_keys_str_mv AT morozovatl hixozideintherapyoftuberculosisofbronchi
AT barinboymon hixozideintherapyoftuberculosisofbronchi
AT doktorovanp hixozideintherapyoftuberculosisofbronchi
AT danilovan hixozideintherapyoftuberculosisofbronchi